^
    No biomarker
    Cervical Cancer
    Krabeva (bevacizumab biosimilar)
    Sensitive
    :
    A1
    Biocon Press Release - 2wk
    BRCA1 mutation + TP53 R248Q
    Cervical Cancer
    bevacizumab + olaparib
    Sensitive
    :
    C4
    J Med Case Rep - 2wk
    No biomarker
    Cervical Cancer
    Aybintio (bevacizumab biosimilar)
    Sensitive
    :
    A1
    No biomarker
    Cervical Cancer
    Mvasi (bevacizumab biosimilar)
    Sensitive
    :
    A1
    No biomarker
    Cervical Cancer
    Zirabev (bevacizumab biosimilar)
    Sensitive
    :
    A1
    PD-L1 expression
    Cervical Cancer
    pembrolizumab
    Sensitive
    :
    A1
    No biomarker
    Cervical Cancer
    bevacizumab
    Sensitive
    :
    A1
    No biomarker
    Cervical Cancer
    Bevax (bevacizumab biosimilar)
    Sensitive
    :
    A1
    No biomarker
    Cervical Cancer
    paclitaxel + topotecan
    Sensitive
    :
    A2
    No biomarker
    Cervical Cancer
    5-fluorouracil
    Sensitive
    :
    A2
    No biomarker
    Cervical Cancer
    paclitaxel
    Sensitive
    :
    A2
    No biomarker
    Cervical Cancer
    carboplatin
    Sensitive
    :
    A2
    No biomarker
    Cervical Cancer
    vinorelbine tartrate
    Sensitive
    :
    A2
    No biomarker
    Cervical Cancer
    pemetrexed
    Sensitive
    :
    A2
    No biomarker
    Cervical Cancer
    mitomycin
    Sensitive
    :
    A2
    No biomarker
    Cervical Cancer
    irinotecan
    Sensitive
    :
    A2
    No biomarker
    Cervical Cancer
    ifosfamide
    Sensitive
    :
    A2
    No biomarker
    Cervical Cancer
    gemcitabine
    Sensitive
    :
    A2
    No biomarker
    Cervical Cancer
    docetaxel
    Sensitive
    :
    A2
    No biomarker
    Cervical Cancer
    albumin-bound paclitaxel
    Sensitive
    :
    A2
    No biomarker
    Cervical Cancer
    topotecan
    Sensitive
    :
    A2
    NTRK3 fusion
    Cervical Cancer
    entrectinib
    Sensitive
    :
    A2
    NTRK2 fusion
    Cervical Cancer
    entrectinib
    Sensitive
    :
    A2
    NTRK1 fusion
    Cervical Cancer
    entrectinib
    Sensitive
    :
    A2
    NTRK3 fusion
    Cervical Cancer
    larotrectinib
    Sensitive
    :
    A2
    NTRK2 fusion
    Cervical Cancer
    larotrectinib
    Sensitive
    :
    A2
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES